CRXM Taxus Cardium Pharmaceuticals
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.
Company profile
Ticker
CRXM
Exchange
Website
CEO
Christopher J. Reinhard
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
Aries Ventures Inc, Cardium Therapeutics, Inc., Casmyn Corp, Taxus Cardium Pharmaceuticals Group Inc.
SEC CIK
Corporate docs
IRS number
840635673
CRXM stock data
()
Calendar
4 Dec 18
13 Apr 21
31 Dec 21
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Mar 21 | Jemapete Christopher J | Common Stock | Buy | Aquire P | No | No | 0.402 | 200,000 | 80.4K | 4,000,000 |
| 16 Mar 21 | Jemapete Christopher J | Common Stock | Buy | Aquire P | No | No | 0.0399 | 300,000 | 11.97K | 3,800,000 |
Financial report summary
?Competition
Gilead SciencesContent analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
amenable, anniversary, asserted, bionomial, BLA, encompassing, GenerxTM, lattice, microstructural, Modernization, noncontrolling, shortly, situ, USPTO
Removed:
accrue, annum, arising, assured, Berlex, Bulletin, canceled, case, CE, certification, collectability, customary, determinable, discontinued, dissolution, eliminating, formed, fourth, half, implemented, invested, iv, largest, lon, mandatorily, mark, maximum, met, move, mulroy, originally, park, performed, persuasive, piggyback, preference, receivable, refusal, Russia, SAB, supplement, title, trailing, tyler, unregistered, unused, utilized
Financial reports
NT 10-Q
Notice of late quarterly filing
4 Dec 18
NT 10-Q
Notice of late quarterly filing
16 May 18
NT 10-Q
Notice of late quarterly filing
14 Nov 17
NT 10-Q
Notice of late quarterly filing
14 Aug 17
10-K
2016 FY
Annual report
27 Jul 17
10-Q
2017 Q1
Quarterly report
27 Jul 17
NT 10-Q
Notice of late quarterly filing
15 May 17
NT 10-K
Notice of late annual filing
29 Mar 17
10-Q
2016 Q3
Quarterly report
20 Mar 17
10-Q
2016 Q2
Quarterly report
5 Mar 17
Current reports
8-K
Gene Biotherapeutics Secures Investment from Nostrum Pharmaceuticals, LLC
28 May 20
8-K
Gene Biotherapeutics Announces Director Retirement
20 Mar 19
8-K
Gene Biotherapeutics Announces Sale of Excellagen Technology
12 Sep 18
8-K
Taxus Cardium Announces Name
8 Jan 18
8-K
Regulation FD Disclosure
9 Jan 17
8-K
Regulation FD Disclosure
4 Jan 17
8-K
Angionetics to Present at Two San Francisco-based Healthcare
3 Jan 17
8-K
Taxus Cardium Announces Two Director Retirements
13 Dec 16
8-K
Entry into a Material Definitive Agreement
2 Oct 16
8-K
Entry into a Material Definitive Agreement
26 Sep 16
Registration and prospectus
25
Voluntary exchange delisting
12 Jan 14
424B5
Prospectus supplement for primary offering
4 Apr 13
424B5
Prospectus supplement for primary offering
12 Feb 12
424B5
Prospectus supplement for primary offering
15 Nov 11
SC TO-I/A
Issuer tender offer statement (amended)
2 Jan 11
SC TO-I/A
Issuer tender offer statement (amended)
15 Dec 10
SC TO-I
Issuer tender offer statement
1 Dec 10
424B5
Prospectus supplement for primary offering
28 Sep 10
S-3/A
Shelf registration (amended)
22 Aug 10
S-3
Shelf registration
8 Aug 10
Proxies
DEF 14A
Definitive proxy
27 May 15
DEF 14A
Definitive proxy
29 Apr 14
DEFA14A
Additional proxy soliciting materials
20 Jun 13
DEFA14A
Additional proxy soliciting materials
5 Jun 13
DEFA14A
Additional proxy soliciting materials
27 May 13
DEF 14A
Definitive proxy
28 Apr 13
PRER14A
Preliminary revised proxy
24 Apr 13
PRE 14A
Preliminary proxy
15 Apr 13
DEF 14A
Definitive proxy
23 Apr 12
DEF 14A
Definitive proxy
26 Apr 11
Other
UPLOAD
Letter from SEC
28 Apr 13
CORRESP
Correspondence with SEC
24 Apr 13
UPLOAD
Letter from SEC
24 Apr 13
UPLOAD
Letter from SEC
13 Apr 11
CORRESP
Correspondence with SEC
10 Apr 11
CORRESP
Correspondence with SEC
17 Mar 11
CORRESP
Correspondence with SEC
9 Mar 11
CORRESP
Correspondence with SEC
1 Mar 11
CORRESP
Correspondence with SEC
6 Jan 11
CORRESP
Correspondence with SEC
22 Dec 10
Ownership
4
Gene Biotherapeutics / Christopher J Jemapete ownership change
18 Mar 21
SC 13D/A
Gene Biotherapeutics / Jemapete Christopher J ownership change
18 Mar 21
SC 13D
Gene Biotherapeutics / Jemapete Christopher J ownership change
1 Mar 21
3
Gene Biotherapeutics / Christopher J Jemapete ownership change
1 Mar 21
SC 13G
Gene Biotherapeutics / Coluccio Christian F ownership change
22 Dec 20
3
Gene Biotherapeutics / NIRMAL MULYE ownership change
17 Aug 20
3
Gene Biotherapeutics / James L Grainer ownership change
14 Aug 20
3
Gene Biotherapeutics / Kaushik K. Vyas ownership change
8 Jul 20
3
Gene Biotherapeutics / Ronald J. Shebuski ownership change
8 Jul 20
3
Initial statement of insider ownership
1 Jun 20